Julia Kern
study nurse
Medizinische Onkologie und Hämatologie · Dept. I
Liquid biopsy to diagnose and monitor central nervous system (CNS) involvement in high-risk B cell non-Hodgkin lymphoma
Apr 10, 2024
Clinical Studies - Apr 10, 2024 - Dec 31, 2099
Ongoing
Project leader: Sturm Andreas
Members: Kern Julia, Quinter Janine
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer
Nov 30, 2022Diese Studie wird durchgeführt, um mehr über AMG 509 als Monotherapie (Einzelmedikament) und AMG 509 in Kombination mit Abirateron oder Enzalutamid oder Pemb-rolizumab bei Patienten mit metastasiertem kastrationsre-sistentem Prostatakrebs (mCRPC) zu...
Clinical Studies - Nov 30, 2022 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Kern Julia, Quinter Janine
EDO-GLIOBLASTOM (S1001-1066)
Oct 10, 2022A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients with Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma
Clinical Studies - Oct 10, 2022 - May 3, 2024
Automatically Closed
Project leader: Hundsberger Thomas
Members: Kern Julia, Müller Fiona
Phase 1/Phase 2 Studie zur Beurteilung der Sicherheit und Verträglichkeit von MK-1088 als Monotherapie und in Kombination mit Pembrolizumab bei Teilnehmenden mit fortgeschrittenen soliden Tumoren
Jul 8, 2022
Clinical Studies - Jul 8, 2022 - Aug 13, 2024
Completed
Project leader: Hess Dagmar
Members: Kern Julia, Quinter Janine
Randomisierte Phase-3-Studie mit DS-1062a im Vergleich zu Docetaxel bei zuvor behandeltem fortgeschrittenem oder metastasi e rtem nicht-kleinzelligem Lungenkrebs ohne verwertbare genomische Veränderungen (TROPION-LungOl)
Oct 8, 2021Eine randomisierte Studie bei Patienten mit metastasiertem Nicht-Kleinzelligen Bronchialkarzinom bei welchen der Tumor nach Chemotherapie und Immuntherapie weiter fortschreitet. Die Studie untersucht die Behandlungsresultate mit dem Antikörper- W...
Clinical Studies - Oct 8, 2021 - Oct 27, 2099
Ongoing
Project leader: Früh Martin
Members: Kern Julia, Quinter Janine
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98
Oct 1, 2021
Clinical Studies - Oct 1, 2021 - Dec 31, 2099
Ongoing
Project leader: Lips Carolin
Members: Kern Julia, Quinter Janine
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer(KEYNOTE-B99)
Sep 29, 2021
Clinical Studies - Sep 29, 2021 - Jan 12, 2024
Completed
Project leader: Lips Carolin
Members: Kern Julia, Quinter Janine
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
Apr 14, 2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Clinical Studies - Apr 14, 2021 - Dec 31, 2099
Ongoing
Project leader: Jörger Markus
Members: Kern Julia, Quinter Janine
IELSG 45
Jun 7, 2019A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymp...
Clinical Studies - Jun 7, 2019 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Kern Julia, Müller Fiona
Peace-4
Apr 26, 2019Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...
Clinical Studies - Apr 26, 2019 - Dec 31, 2099
Ongoing
Project leader: Fischer Stefanie
Members: Kern Julia, Quinter Janine
MK-3475-495: KeylmPaCT
Dec 12, 2018A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT).
Clinical Studies - Dec 12, 2018 - Dec 31, 2099
Ongoing
Members: Fehr Martin, Kern Julia, Müller Fiona